Loading clinical trials...
Loading clinical trials...
A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer
Conditions
Interventions
Nivolumab
Visugromab (CTL-002)
+1 more
Locations
4
Italy
IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University
Milan, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica
Roma, Italy
A.O.U. Città della Salute e della Scienza di Torino
Torino, Italy
Start Date
September 6, 2023
Primary Completion Date
October 16, 2025
Completion Date
October 16, 2026
Last Updated
December 11, 2025
NCT06257264
NCT07206225
NCT03317158
NCT06253871
NCT06510374
NCT06503146
Lead Sponsor
CatalYm GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions